BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bctx · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.09
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.94 | ↓ 5.00% |
1-day model range: $2.85–$3.02. Peak: $3.02 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · BCTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-09-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-09-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on BriaCell Therapeutics Corp. (BCTX) stock. Of the recent 10 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover BCTX.
Analyst Recommendation Trends
BCTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$2M
EPS This Year
$-3.01
EPS Next Year
$-11.45
↑ 280.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast BCTX EPS of $-3.01 for the current fiscal year, based on estimates from 1 analysts. The BCTX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BCTX stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BCTX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The BCTX short-term stock prediction for tomorrow is $2.94 (-5.00%).
BriaCell Therapeutics Corp. trades on NASDAQ under the ticker BCTX. The BCTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
BCTX forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month BCTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.09.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.